Search Results
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
August, 2024
August 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jul
amol akhade
May 27, 2024, 05:50 |
Blog
Amol Akhade: A Talk about critical analysis of oncology trials in cancer Institute Adyar
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X: “Gave A…
May 5, 2024, 01:02 |
Blog
Amol Akhade: Does this ring bell for other oral drugs also?
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X: “Optimal…
Apr 24, 2024, 22:44 |
Blog
Amol Akhade: Can u pronounce name of this latest approved drug by US FDA correctly?
Amol Akhade, Consultant medical oncologist at Suyog Cancer Clinics, shared a post on X: "Can u…
Mar 8, 2024, 15:26 |
Blog
Amol Akhade: The official statement issued by Tata Memorial Hospital regarding the recent social media discussion about research done by Professor Dr. Mitra and colleagues at TMH
Mar 3, 2024, 06:41 |
Blog
Amol Akhade: How price per pill of lenalidomide kept on rising in USA
Amol Akhade, Consultant medical oncologist at Suyog Cancer Clinics, shared on X/Twitter: "How price per pill…
Feb 14, 2024, 06:32 |
Insight
Amol Akhade: What is the approach of Indian Oncologist Towards Drug approval agencies?
Amol Akhade, Consultant medical oncologist at Suyog Cancer Clinics, shared on X/Twitter: "What is the…
Feb 4, 2024, 23:52 |
Blog
Amol Akhade: So we need to make sure that low and lower middle income countries have improved access to cancer care
Amol Akhade, Consultant Medical Oncologist/Hematologist at Suyog Cancer Clinics, posted on X: “4th Feb is…
Nov 29, 2023, 19:32 |
Drugs
Amol Akhade: India made cervical cancer vaccine is non inferior to original made by MSD in phase 2/3 RCT
Amol Akhade, Consultant Medical Oncologist/Hematologist at Suyog Cancer Clinics, posted on Twitter: “So India made…
Nov 26, 2023, 11:39 |
Blog
Amol Akhade: Showing lacunas in ADAURA is considered as SIN in oncology
Dr Amol Akhade, Consultant medical oncologist/hematooncologist at Suyog Cancer Clinics, posted on X/Twitter: "Showing lacunas…
Oct 21, 2023, 19:37 |
Blog
Amol Akhade: Do we need to study every new IO drug against Pembrolizumab plus chemo in first line NSCLC? NO.
Amol Akhade, Senior Consultant in Medical and Hematooncology at the Dr Hitendra Patil's Suyog Cancer…
1
2
3
All:
28
Posts:
11 - 20
New management team at St. Anna Children's Hospital
Key Inspirational Moments with WHO Director at the Olympic Games
Remembering Susan Wojcicki, Honoring a Legacy of Leadership and Technological Innovation
MASCC24 Highlights: The Ideal Location for Care Varies According to Disease, Patient and Family Characteristics
Highlights on the U.S. - India Cancer Moonshot Dialogue
Facebook
RSS Feed
Twitter
Linkedin
Youtube